Identification
- Generic Name
- Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells
- DrugBank Accession Number
- DB15740
- Background
Human olfactory mucosa-derived mesenchymal stem cells (OM-MSCs) reside in an accessible location of the nasal cavity and have properties of multipotency and high proliferation, which contributes to high potential for regenerative medicine. In humans, OM-MSCs are derived from the olfactory mucosa which is collected in vivo through rhinoscopy techniques and nasal forceps. OM-MSCs are also immunomodulatory and have potential for treating immunological diseases. Currently, OM-MSCs does not have wide application as there is not yet a standard and unambiguous protocol for OM-MSC collection, isolation, and therapeutic application.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Cell transplant therapies
Other cell transplant therapies - Synonyms
- hOM-MSC
- Olfactory mucosa mesenchymal stem cells
- Olfactory mucosa mesenchymal stem/stromal cells
- Olfactory mucosa mesenchymal stromal cells
- OM-MSC
- External IDs
- Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
OM-MSCs’ immunomodulating activities are partially related to CD4+ T-lymphocytes, B-lymphocytes, macrophages, and dendritic cells. OM-MSCs were also found to suppress cytotoxic functions of CD8 + cytotoxic lymphocytes and natural killer cells. Potential applications include in the field of experimental neurology to employ it for treatment of different types of lesions and neurodegenerative diseases of the central nervous system, hippocampal lesions, regeneration of peripheral nerves and cranial nerves, and for spinal cord trauma. There are also potentials for immunosuppression for autoimmune diseases and regenerative promotion for myocardial tissue after infarction and also against ischemic tissues.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- Alvites RD, Branquinho MV, Caseiro AR, Amorim I, Santos Pedrosa S, Rema A, Faria F, Porto B, Oliveira C, Teixeira P, Magalhaes R, Geuna S, Varejao ASP, Mauricio AC: Rat Olfactory Mucosa Mesenchymal Stem/Stromal Cells (OM-MSCs): A Characterization Study. Int J Cell Biol. 2020 Jan 29;2020:2938258. doi: 10.1155/2020/2938258. eCollection 2020. [Article]
- Company Article [Link]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1, 2 Completed Treatment Coronavirus Disease 2019 (COVID‑19) / COVID / Infections, Coronavirus / Interstitial Pneumonitis / Pneumonia / Viral Pneumonia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at August 11, 2020 20:55 / Updated at August 13, 2020 07:02